Biomet, Inc. (BMET-NASDAQ) has recived and accepted a higher buyout price for shareholders. The company announced that it has unanimously recommended to shareholders an increased offer from a private equity consortium to acquire Biomet for $46.00 per share in cash. This $11.4 Billion deal is a sweetened offer from the private equity consortium including affiliates of the Blackstone Group, Goldman Sachs Capital Partners, Kohlberg Kravis Roberts & Co. and TPG. This will commence on June 14, 2007.
Morgan Stanley provided the Board of Directors with its opinion that the revised merger agreement is fair from a financial point of view to holders of Biomet common stock. Completion of the tender offer is subject to the condition that at least 75% of the Biomet common shares have been tendered in the offer, which is the same percentage approval requirement as with the previous merger structure.
As a result, Biomet announced that it has cancelled the special meeting of shareholders previously scheduled for Friday, June 8 to consider and vote on the original merger agreement AND has agreed not to pay its annual dividend. Sharesare trading up 3% at $25.60 in pre-market activity, which is a new 52-week and 24-month high. It is also at the high-end of an old trading range from back in 2004, so this new improved merger price will essentially make just about all shareholders whole.
Jon C. Ogg
June 7, 2007
Jon Ogg can be reached at email@example.com; he does not own securities in the companies he covers.